This course has been accredited with 3 CME credits by the UEMS EACCME. Radiolabelled prostate-specific membrane antigen (PSMA) is increasingly used in imaging and treatment of prostate cancer. PSMA-directed radionuclide therapy is an efficacious new treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC) and beyond. The online course will cover the spectrum of radiolabelled […]
This course provides a comprehensive update on instrumental and radiopharmaceutical innovations in the diagnosis and treatment of neuroblastoma. Participants will explore current and emerging imaging modalities, with a comparative analysis of MIBG, MFBF, FDOPA, and Gallium-based tracers, highlighting their evolving roles in staging, risk stratification, and response assessment. The course will address recent changes in […]
This webinar will be on the future of cancer staging with hybrid imaging technologies. Participants will gain an overview of advanced PET/CT, SPECT/CT, and PET/MRI systems, learning how hybrid imaging enhances diagnostic accuracy and supports more precise clinical decisions.The session will explore the practical challenges technologists face when working with these cutting-edge systems, including image […]
Alzheimer’s disease is a growing global health concern, now facing a pivotal moment with the approval of disease-specific treatments. This Focus Meeting brought together international experts under the theme ‘An accurate diagnosis for an effective treatment with Molecular Imaging’ to explore the crucial role of imaging and biomarkers in improving diagnosis, treatment selection, and monitoring. The goal […]
This webinar will examine the fundamental differences between targeted radionuclide therapy (TRT) and conventional external beam radiotherapy (EBRT), integrating physical, dosimetric, and radiobiological perspectives relevant to clinical practice. Drawing on the EANM–ESTRO joint session, the first part will outline how TRT’s systemic administration, patient-specific pharmacokinetics, protracted low dose-rate delivery, and highly heterogeneous intratumoral distribution distinguish […]
This intensive 1,5-day course bridges the gap between radiobiology, dosimetry, and clinical practice in targeted radionuclide therapy. Designed for early-career nuclear medicine physicians and medical physicists, the programme explores dose-response relationships in the three most commonly used theranostic molecules: somatostatin-ligands for neuroendocrine tumours, PSMA-inhibitors for prostate cancer, and radioiodine for thyroid malignancies. Through a balanced […]
Imaging of infection and inflammation has been part of nuclear medicine since the 1970s. Over the past two decades, the growing role of FDG PET/CT in diagnosing and monitoring the treatment of a wide variety of infectious and inflammatory diseases has been recognised. As a result, this technique has recently been adopted in several clinical […]
This webinar will cover synergetic information derived from the CT component in SPECT/CT and PET/CT examinations: the first part we will focus on cardiac calcifications, offering valuable insights into their detection and clinical relevance especially for myocardial perfusion scans. In the second half, we will discuss incidental findings in the thorax, helping clinicians recognize and […]
This 1,5-day course focuses on the growing field of integrated imaging in infectious and inflammatory diseases in children, with an emphasis on hybrid imaging. The panelists will introduce the participants to the specific aspects of paediatric patients in this growing field, covering the most relevant topics of the clinical scenario and the technical options available […]
Targeted Radionuclide Therapy (TRT) is an expanding field of cancer treatment in which radiopharmaceuticals—comprising a radionuclide linked to a tumour-targeting biological vector—are administered to deliver cytotoxic radiation doses selectively to malignant tissues. The growing development of theragnostic agents, enabling both imaging and therapy, has strengthened the rationale for a patient-specific treatment approach. In clinical trials, […]
This presentation provides an overview of fibroblast activation protein (FAP)–directed molecular imaging as a novel approach for tumour staging and theranostic decision-making across multiple malignancies. It introduces the biological role of cancer-associated fibroblasts and stromal remodeling in tumour progression and highlights the rationale for FAP-targeted PET imaging. Clinical evidence from prospective trials and comparative imaging […]
"Bringing Therapy Radioisotopes into Clinical Radiopharmacy" is an advanced course designed to bridge the gap between isotope production, radiopharmaceutical preparation and clinical application. This course focuses on the practical and regulatory hurdles of integrating therapeutic radionuclides into hospital settings. Diving into production and purification methods of emerging therapeutic isotopes, supply chain and matched pairs for theranostics, […]
